N-{[1-(2,4-dichlorobenzyl)piperidin-4-yl]methyl}-5-methoxy-1H-indazole-3-carboxamide | 1452520-13-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-{[1-(2,4-dichlorobenzyl)piperidin-4-yl]methyl}-5-methoxy-1H-indazole-3-carboxamide
• 英文别名: N-[[1-[(2,4-dichlorophenyl)methyl]piperidin-4-yl]methyl]-5-methoxy-1H-indazole-3-carboxamide
• CAS: 1452520-13-6
• 化学式: C₂₂H₂₄Cl₂N₄O₂
• 分子量: 447.364
• InChiKey: YCTKWXLLTRJPAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  70.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-甲氧基-3-吲唑羧酸 在 氯化亚砜 、 三乙胺 作用下， 以 甲苯 为溶剂， 反应 16.0h， 生成 N-{[1-(2,4-dichlorobenzyl)piperidin-4-yl]methyl}-5-methoxy-1H-indazole-3-carboxamide
  参考文献：
  名称：

  [EN] USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS
  [FR] UTILISATION DES COMPOSÉS 1H-INDAZOLE-3-CARBOXAMIDE EN TANT QU'INHIBITEURS DE LA GLYCOGÈNE SYNTHASE KINASE 3 BÊTA

  摘要：

  1- H-吲唑-3-羧酰胺化合物作为糖原合成酶激酶3β抑制剂。本发明涉及用于作为糖原合成酶激酶3β（GSK-33）抑制剂的1- H-吲唑-3-羧酰胺化合物，以及它们在治疗GSK-3β相关疾病中的应用，例如（i）胰岛素抵抗性疾病；（ii）神经退行性疾病；（iii）情绪障碍；（iv）精神分裂症性障碍；（v）癌症性障碍；（vi）炎症；（vii）物质滥用障碍；以及（viii）癫痫。

  公开号：

  WO2013124169A1

文献信息

• [EN] USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS<br/>[FR] UTILISATION DES COMPOSÉS 1H-INDAZOLE-3-CARBOXAMIDE EN TANT QU'INHIBITEURS DE LA GLYCOGÈNE SYNTHASE KINASE 3 BÊTA
  申请人：ACRAF

  公开号：WO2013124169A1

  公开（公告）日：2013-08-29

  1 H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1 H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-33) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.

  1- H-吲唑-3-羧酰胺化合物作为糖原合成酶激酶3β抑制剂。本发明涉及用于作为糖原合成酶激酶3β（GSK-33）抑制剂的1- H-吲唑-3-羧酰胺化合物，以及它们在治疗GSK-3β相关疾病中的应用，例如（i）胰岛素抵抗性疾病；（ii）神经退行性疾病；（iii）情绪障碍；（iv）精神分裂症性障碍；（v）癌症性障碍；（vi）炎症；（vii）物质滥用障碍；以及（viii）癫痫。
• Hit Optimization of 5-Substituted-<i>N</i>-(piperidin-4-ylmethyl)-1<i>H</i>-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders
  作者：Guido Furlotti、Maria Alessandra Alisi、Nicola Cazzolla、Patrizia Dragone、Lucia Durando、Gabriele Magarò、Francesca Mancini、Giorgina Mangano、Rosella Ombrato、Marco Vitiello、Andrea Armirotti、Valeria Capurro、Massimiliano Lanfranco、Giuliana Ottonello、Maria Summa、Angelo Reggiani

  DOI：10.1021/acs.jmedchem.5b01208

  日期：2015.11.25

  Novel treatments for bipolar disorder with improved efficacy and broader spectrum of activity are urgently needed. Glycogen synthase kinase 3 beta (GSK-3 beta) has been suggested to be a key player in the pathophysiology of bipolar disorder. A series of novel GSK-3 beta inhibitors having the common N-[(1-alkylpiperidin-4-yl)methyl]-1H-indazole-3-carboxamide scaffold were prepared taking advantage of an X-ray cocrystal structure of compound 5 with GSK-3 beta. We probed different substitutions at the indazole 5-position and at the piperidine-nitrogen to obtain potent ATP-competitive GSK-3 beta inhibitors with good cell activity. Among the compounds assessed in the in vivo PK experiments, 14i showed, after i.p. dosing, encouraging plasma PK profile and brain exposure, as well as efficacy in a mouse model of mania. Compound 14i was selected for further in vitro/in vivo pharmacological evaluation, in order to elucidate the use of ATP-competitive GSK-3 beta inhibitors as new tools in the development of new treatments for mood disorders
• USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS
  申请人：AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. - S.p.A.

  公开号：EP2817301B1

  公开（公告）日：2015-12-23
• US9163013B2
  申请人：——

  公开号：US9163013B2

  公开（公告）日：2015-10-20
• US9700551B2
  申请人：——

  公开号：US9700551B2

  公开（公告）日：2017-07-11